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Abstract  23 
Following neurotrauma, secondary degeneration of neurons and glia adjacent to the injury 24 
leads to further functional loss. A combination of ion channel inhibitors (lomerizine + oxATP 25 
+ YM872) has been shown to be effective at limiting structural and functional loss due to 26 
secondary degeneration. Here we assess efficacy of the combination where oxATP is 27 
replaced with Brilliant Blue G (BBG), a more clinically applicable P2X7 receptor inhibitor. 28 
Partial optic nerve transection was used to model secondary degeneration in adult female rats. 29 
Animals were treated with combinations of lomerizine + YM872 + oxATP or lomerizine + 30 
YM872 + BBG, delivered via osmotic mini pump directly to the injury site. Outcomes 31 
assessed were Iba1+ and ED1+ microglia and macrophages, oligodendroglial cell numbers, 32 
node/paranode structure and visual function using the optokinetic nystagmus test. The 33 
lomerizine + BBG + YM872 combination was at least as effective at the tested 34 
concentrations as the lomerizine + oxATP + YM872 combination at preserving 35 
node/paranode structure and visual function when delivered locally. However, neither ion 36 
channel inhibitor combination significantly improved microglial/macrophage nor 37 
oligodendroglial numbers compared to vehicle treated controls. In conclusion, a locally 38 
delivered combination of ion channel inhibitors incorporating lomerizine + BBG + YM872 is 39 
at least as effective at limiting secondary degeneration following partial injury to the optic 40 
nerve as the combination incorporating oxATP.  41 
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Introduction 47 
Following neurotrauma, a series of metabolic and structural changes are propagated in 48 
initially undamaged tissue, associated with increased intracellular Ca2+, oxidative stress and 49 
apoptotic cell death of neurons and glia (Dong et al. 2009). Since the initial insult is often 50 
unavoidable, treatments for functional recovery after neurotrauma focus heavily on limiting 51 
this secondary damage (Doan et al. 2016). However, despite extensive research, effective 52 
pharmacotherapeutic treatments for secondary degeneration following neurotrauma are 53 
limited (Kwon et al. 2011). In order to successfully limit secondary degeneration following 54 
neurotrauma, it is important to test efficacy of treatments in appropriate animal models of 55 
injury. Partial optic nerve transection is an established and useful model for investigating 56 
secondary degeneration, where the dorsal optic nerve of adult rats is partially transected, 57 
allowing for spatial separation between the primary and subsequent secondary degeneration 58 
(Levkovitch-Verbin et al. 2003; Blair et al. 2005). The model has been further characterised 59 
and employed to assess efficacy of pharmacotherapeutics for secondary degeneration, 60 
delivered directly to the injury site using osmotic mini-pumps (Fitzgerald et al. 2009a; 61 
Fitzgerald et al. 2009b; Savigni et al. 2013; O'Hare Doig et al. 2017).  62 
Secondary degeneration is characterised by a myriad of reactive metabolic pathways, 63 
including inflammation, excitotoxicity, mitochondrial dysfunction and oxidative stress, 64 
associated with structural deficits, dysmyelination and apoptotic cell death (Tymianski and 65 
Charles 1996; Dong et al. 2009; Maxwell 2013). Ca2+ overload is considered to be a major 66 
trigger for the toxic mechanisms of secondary degeneration (Farooqui et al. 2008). Using the 67 
partial optic nerve transection model, we have previously demonstrated that a locally 68 
delivered combinatorial treatment strategy to limit excess Ca2+ influx through voltage gated 69 
calcium channels, P2X7 receptors and Ca
2+ permeable AMPA receptors with lomerizine, 70 
oxATP and YM872 respectively, reduced myelin decompaction, preserved node/paranode 71 
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structure and visual function (Savigni et al. 2013). Acute outcomes indicated that early 72 
preservation of node/paranode structure and OPC numbers was associated with longer term 73 
preservation of visual function (O'Hare Doig et al. 2017).  74 
Following mild traumatic brain injury, it is currently unclear as to whether there is a blood 75 
brain barrier breach, with studies reporting varying degrees of compromise of blood brain 76 
barrier integrity following injury (Deford et al. 2002; Tomkins et al. 2011; Zetterberg et al. 77 
2013). Therefore, pharmacotherapies designed to treat all but the most severe cases of 78 
neurotrauma, need to be able to travel across the closed blood brain barrier following 79 
systemic delivery. oxATP does not appear to be able to cross the blood brain barrier (Peng et 80 
al. 2009). Thus, for clinical applicability of the lomerizine, oxATP and YM872 combination, 81 
oxATP needs to be substituted with a blood brain barrier permeable P2X7 receptor 82 
antagonist. Here we introduce an alternative P2X7 receptor inhibitor Brilliant Blue G (BBG) 83 
to the combination. BBG has previously shown therapeutic effects following neurotrauma 84 
(Peng et al. 2009; Kimbler et al. 2012; Wang et al. 2015), and importantly, can cross the 85 
closed blood brain barrier (Wong et al. 2011). This study compared the efficacy of the ion 86 
channel inhibitor combination of lomerizine + BBG + YM872 to a combination with 87 
lomerizine + oxATP + YM872 for limiting secondary degeneration and restoring function 88 
following partial optic nerve transection.  89 
 90 
Methods 91 
Animals and study design 92 
Thirty-eight adult, female PVG rats were obtained from the Animal Resource Centre in 93 
Murdoch, Western Australia. The animals were housed under 12-hour light/dark cycles with 94 
ad libitum access to food and water. All procedures were approved by the University of 95 
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Western Australia Animal Ethics Committee (approval number RA3/100/1485) and were in 96 
accordance with the National Health and Medical Research Council (NHMRC) of Australia 97 
Code of Practice for use of Animals for Scientific Purposes. The animals were divided into 98 
four experimental groups, a sham injured, vehicle treated group (n = 8); an injured, vehicle 99 
treated group (n = 10); an injured, lomerizine + oxATP + YM872 treated group (n = 10); and 100 
an injured, lomerizine + BBG + YM872 treated group (n =10); with the sham group serving 101 
as an uninjured, vehicle treated control. 102 
Surgical procedures 103 
Partial optic nerve transection (day 1) and left eyelid suturing (day 3) were performed as 104 
previously described (Fitzgerald et al. 2009a), under Ketamine (Ketamil, 50mg/kg, Troy 105 
Laboratories) and Xylazine (Ilium Xylazil, 10mg/kg, Troy Laboratories) anaesthesia 106 
administered intraperitoneally. In brief, for the partial transection surgery: the skin overlying 107 
the skull behind the right eye was incised. The optic nerve was accessed and the nerve 108 
parenchyma exposed by making a longitudinal cut in the sheath using fine iridectomy 109 
scissors. About 1mm behind the right eye, the dorsal aspect of the optic nerve was partially 110 
lesioned to a depth of approximately 200μm with a diamond radial keratotomy knife 111 
(Geuder); the depth determined by the protrusion of the blade beyond the surrounding guard. 112 
Sham injury included all procedures except the cut in the sheath and the partial optic nerve 113 
lesion. Surgical implantation of Alzet osmotic mini-pumps was performed as described 114 
(Savigni et al. 2013). Immediately following surgery, subcutaneous injections of analgesia 115 
(2.8mg/kg carprofen, Norbrook) and 1mL sterile phosphate buffered saline (PBS) were 116 
administered. 117 
Treatments 118 
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Lomerizine (30mg/kg, LKT Labs©) was orally administered in butter vehicle twice daily 8 119 
hours apart, until end of experiment, commencing once animals were ambulatory following 120 
surgery as previously described (Fitzgerald et al. 2009a). oxATP (1mM), BBG (540μM) and 121 
YM872 (240μM) were delivered via osmotic mini-pump at 0.5μL/h in PBS vehicle. 122 
Concentrations employed for oxATP and YM872 were consistent with our previous studies 123 
where efficacy was demonstrated (Savigni et al. 2013), and the BBG dose was chosen with 124 
reference to the literature describing efficacy of BBG and YM872 in related models 125 
(Takahashi et al. 2002; Diaz-Hernandez et al. 2012; Cervetto et al. 2013). The sham injured 126 
and partial optic nerve transection injured, vehicle treated experimental groups both received 127 
PBS via osmotic mini-pump and butter orally, administered as described for the inhibitor 128 
treated groups.  129 
Behavioural assessment 130 
On day 3, the animals were anaesthetised as described above and their uninjured left eyelids 131 
sutured shut. The optokinetic nystagmus assessment of visual function was performed on day 132 
4 for all animals, in accordance with established procedures (Fitzgerald et al. 2010b). 133 
Animals were videoed and number of responses per unit time engaged in the task was 134 
determined by a single investigator blinded to animal identity. Note that due to a procedural 135 
error, n = 5 for the injured, vehicle treated group. Responses were categorised as either 136 
smooth pursuits or fast resets. Smooth pursuits are characterised as an elongated head 137 
rotation tracking the stripes, and fast resets as a rapid, realigning head movement; both 138 
elements are an indication of visual ability of the animal (Abdeljalil et al. 2005).  139 
Tissue processing and immunohistochemistry 140 
Immediately following behavioural assessment, rats were euthanised with pentobarbitone 141 
sodium (160mg/kg, Delvet), transcardially perfused with 0.9% saline, followed by 4% 142 
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paraformaldehyde (Sigma-Aldrich) in 0.1M PBS. Optic nerves were dissected and fixation 143 
continued overnight by immersion in 4% paraformaldehyde. Tissue was transferred into 15% 144 
sucrose (Chem Supply) in PBS, then cryosectioned in longitudinal orientation at a thickness 145 
of 14µm and collected onto Superfrost Plus glass microscope slides. Immunohistochemistry 146 
was conducted in accordance with established procedures(Fitzgerald et al. 2010a) using 147 
primary antibodies recognising: microglial activation markers Iba1 (1:500; Abcam, goat 148 
Ab5076) and ED1 (1:500; Merck Millipore, mouse MAB1435); oligodendroglial indicators 149 
oligodendrocyte transcription factor 2 (Olig2; 1:500; R&D Systems, goat AF2418) and 150 
platelet-derived growth factor alpha receptor (PDGFαR; 1:500; Abcam Ab96806); and for 151 
paranode and node of Ranvier structures Caspr (1:500; Abcam, rabbit Ab34151), and β-III 152 
tubulin (1:500; Merck Millipore, mouse MAB1637). Antibodies were diluted in PBS 153 
containing 0.2% Triton™ X-100 and 5% normal donkey serum. Secondary antibodies were 154 
Alexa Flour 488 or 555 (1:400; Thermo Fisher Scientific™), together with Hoechst 3342 155 
(1:1000; Thermo Fisher Scientific™) diluted in PBS containing 0.2% Triton™ X-100. 156 
Finally, the sections were mounted and cover slipped using Fluoromount-G (Thermo Fisher 157 
Scientific).  158 
Imaging and Analysis 159 
The ventral optic nerve directly below the site of injury was visualised, with one field of view 160 
from one section per animal imaged for each outcome measure. The slides were viewed using 161 
either a Nikon Ni-E confocal fluorescence microscope (Nikon Corporation) or a Nikon 162 
Eclipse Ti inverted microscope. A series of 13 optical images were taken at 0.5μm 163 
increments along the z-axis, and deconvoluted using Nikon Elements AT software. Imaging 164 
for each outcome measure was performed in a single sitting with consistent capture settings. 165 
All image analysis was performed on Fiji image processing software (NIH) by a single 166 
investigator blinded to section identity. Due to poor fixation and tissue processing in a few 167 
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animals, numbers of animals per group analysed for immunohistochemistry outcomes were: 168 
sham injured, vehicle treated group (n = 8); injured, vehicle treated group (n = 10); injured, 169 
lomerizine + oxATP + YM872 treated group (n = 8); and injured, lomerizine + BBG + 170 
YM872 treated group (n =9). 171 
Total numbers of Iba1+ resident reactive microglia, ED1+ activated microglia/macrophages, 172 
Olig2+ oligodendroglia and Olig2+/PDGFαR+ oligodendrocyte precursor cells (OPCs) were 173 
counted within a region of interest in a 20x image of the ventral nerve directly beneath the 174 
primary injury site and expressed as the mean number of cells/mm2. For node/paranode 175 
analyses, a single 60x z-stack image per animal was divided into a 3 x 3 grid and all 176 
complexes with clearly defined Caspr immunostaining in a single randomly selected grid 177 
square assessed; at least 30 node/paranode complexes were analysed per animal. Outcome 178 
measures were the length of the paranodal gap, defined as the distance between two Caspr+ 179 
areas; paranode length, as defined by the length of Caspr+ areas; and the percentages of 180 
atypical nodal complexes, as previously described (Szymanski et al. 2013).  181 
Statistics 182 
Results were analysed using IBM SPSS software. Outliers were detected using the Tukey 183 
Outlier Detection Model, whereby data that were greater than 1.5 interquartile ranges outside 184 
of the first and third quartiles were considered outliers and removed from the data set. No 185 
more than two outliers were removed per treatment group for each outcome measure, details 186 
provided in figure legends. A single one-way ANOVA encompassing all four treatment 187 
groups were performed for each outcome measure. Normality was assumed, Levene’s test 188 
was used to assess homogeneity of variances for each data set (α = 0.05). If Levene’s test 189 
showed equal variance, the Tukey post-hoc was used; for unequal variance, the Games-190 
Howell post-hoc was applied; both used p ≤ 0.05 to indicate statistical significance.  191 
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Results 193 
Effects of ion channel inhibitor combinations on microglia and macrophages  194 
Numbers of inflammatory cells in ventral optic nerve vulnerable to secondary degeneration 195 
were quantified using Iba1 for resident microglia, ED1 for infiltrating 196 
microglia/macrophages, and colocalised Iba1+/ED1+ for infiltrating microglial cells (Wu et 197 
al. 2005). The numbers of Iba1+ activated resident microglia were different in the various 198 
treatment groups (Figure 1a; F = 3.483, DF = 3, p = 0.028), with the only statistically 199 
significant difference an increase in the number of Iba1+ cells when animals were treated 200 
with lomerizine + BBG + YM872 compared to the sham injured, vehicle treated group (p = 201 
0.029). There was a trend towards increased Iba1+ cells with injury when comparing the 202 
injured, vehicle treated group with the sham injured, vehicle treated group (p = 0.071). There 203 
was no significant difference between the two ion channel inhibitor combinations in the 204 
number of Iba+ cells (p = 0.938).  205 
In contrast, there was a significant difference in numbers of ED1+ infiltrating microglia/ 206 
macrophages (Figure 1b; F = 2.5, DF = 3, p = 0.079), with the numbers of the injured, vehicle 207 
treated group significantly increased compared to sham injured, vehicle treated animals (p = 208 
0.049). The number of ED1+ cells in the groups treated with either of the ion channel 209 
inhibitor combinations were not significantly different to either the injured, vehicle treated 210 
group or the sham injured, vehicle treated group (p > 0.05). There was no significant 211 
difference between the two ion channel inhibitor combinations in the number of ED1+ cells 212 
(p = 0.994).  213 
Similarly, the number of Iba1+/ED1+ infiltrating microglial cells differed with experimental 214 
treatment (Figure 1c; F = 2.912, DF = 3, p = 0.041). A significant increase in the numbers of 215 
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Iba1+/ED1+ cells was observed in the injured, vehicle treated group compared to the sham 216 
injured, vehicle treated group (p = 0.024). Neither of the ion channel inhibitor treatment 217 
groups had significantly reduced numbers of Iba1+/ED1+ cells compared to the injured, 218 
vehicle treated group (p > 0.05). There was no significant difference between the two ion 219 
channel inhibitor combinations in the number of Iba1+/ED1+ cells (p = 0.988). 220 
Representative images of Iba1+ cells, ED1+ cells and Iba1+/ED1+ cells are shown (Figure 221 
1d).  222 
Effects of ion channel inhibitor combinations on oligodendroglia 223 
The densities of Olig2+ oligodendroglia were not different in any of the experimental groups 224 
(Figure 2a; F = 2.042, DF = 3, p = 0.128), example cell shown (Figure 2b). However, when 225 
the analysis was refined to include immunoreactivity to PDGFαR, thereby detecting OPCs 226 
more specifically, there were significant differences between experimental groups (Figure 2c, 227 
d; F = 4.681, DF = 3, p = 0.008). As expected (O'Hare Doig et al. 2017), there was a 228 
significant decrease in the number of OPCs in the injured, vehicle treated group compared to 229 
the sham injured, vehicle treated group (p = 0.007). However, neither ion channel inhibitor 230 
combination groups had significantly increased numbers of OPCs compared to the injured, 231 
vehicle treated group (p > 0.05), and there was no significant difference between the two ion 232 
channel inhibitor combinations in the number of OPCs (p = 0.599).  233 
Effects of ion channel inhibitor combinations on node/paranode complexes 234 
Significant differences in the length of the paranode between experimental groups were 235 
observed (Figure 3a; F = 52.445, DF = 3, p = 0.0001). Partial optic nerve transection resulted 236 
in a significant increase in paranode length in the injured, vehicle treated group compared to 237 
the sham injured, vehicle treated group (p = 0.0001), as expected from previous studies 238 
(Szymanski et al. 2013). While treatment with lomerizine + oxATP + YM872 reduced 239 
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paranode length (p = 0.0001), paranodes remained longer than in the sham injured, vehicle 240 
treated group (p = 0.0001). Treatment with the lomerizine + BBG + YM872 combination also 241 
resulted in significantly reduced paranode lengths compared to the injured, vehicle treated 242 
group (p = 0.0001), to levels significantly different to the sham injured, vehicle treated group 243 
(p = 0.001). Largely similar outcomes were observed when measuring the length of the 244 
paranodal gap, indicative of the length of the node of Ranvier (Figure 3b; F = 20.367, DF = 3, 245 
p = 0.0001). There was no significant difference between the two ion channel inhibitor 246 
combinations in the length of the paranode (p = 0.084) or the paranodal gap (p = 0.122).  247 
There were significant differences between experimental groups in the percentage of atypical 248 
nodal complexes (Figure 3c-e; F = 374.951, DF = 3, p = 0.0001). Atypical nodal complexes 249 
were defined as either a heminode, characterised as a β-III tubulin+ area flanked by only one 250 
Caspr+ area, or a single paranode, defined as a Caspr+ area not associated with a β-III 251 
tubulin+ area (Figure e) (Szymanski et al. 2013). Injury resulted in an increase in the 252 
percentage of atypical nodal complexes in the injured, vehicle treated group compared to the 253 
sham injured, vehicle treated group (p = 0.0001), which was significantly reduced by both 254 
lomerizine + oxATP + YM872 (p = 0.0001) and lomerizine + BBG + YM872 (p = 0.0001). 255 
However, both ion channel inhibitor combination groups still had significantly increased 256 
levels of atypical nodal complexes compared to the sham injured, vehicle treated group (p = 257 
0.0001). There was no significant difference between the two ion channel inhibitor 258 
combinations in the number of atypical nodal complexes (p = 0.668).  259 
Effects of ion channel inhibitor combinations on the optokinetic nystagmus reflex 260 
The optokinetic nystagmus test of visual function, revealed significant differences in the 261 
number of smooth pursuits and fast resets following injury and treatment (Figure 4a; smooth 262 
pursuits F = 7.05, DF = 3, p = 0.001; fast resets F = 7.656, DF = 3, p = 0.001). Injury resulted 263 
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in a significant decrease in the numbers of both smooth pursuits and fast resets by the injured, 264 
vehicle treated group compared to the sham injured, vehicle treated group (p = 0.002, p = 265 
0.001 respectively). Animals treated with lomerizine + oxATP + YM872 made significantly 266 
more smooth pursuits than the injured, vehicle treated group (p = 0.035), but fewer fast resets 267 
than the sham injured, vehicle treated group (p = 0.006). Animals treated with lomerizine + 268 
BBG + YM872 made significantly more smooth pursuits (p = 0.002) and fast rests (p = 269 
0.039) than the injured, vehicle treated group; outcomes were not different from the sham 270 
injured, vehicle treated group (p = 0.992, p = 0.284 respectively). There was no significant 271 
difference between the two ion channel inhibitor combinations in the number of smooth 272 
pursuits (p=0.422) or fast resets (p = 0.222).  273 
To control for the length of the tracking motions, the time engaging in tracking behaviour 274 
was also assessed, giving similar outcomes (Figure 4b; F = 11.458, DF = 3, p = 0.0001). 275 
Injury resulted in a significantly lower proportion of time spent engaging in smooth pursuits 276 
by the injured, vehicle treated group compared to the sham injured, vehicle treated group (p = 277 
0.0001). Animals treated with lomerizine + oxATP + YM872 spent more time tracking than 278 
the injured, vehicle group (p = 0.01), but still less time than the sham injured, vehicle treated 279 
group (p = 0.045). Animals treated with lomerizine + BBG + YM872 also spent significantly 280 
longer performing smooth pursuits than the injured, vehicle treated group (p = 0.0001), and 281 
the time spent tracking was not significantly different to the sham injured, vehicle treated 282 
group (p = 0.161). There was no significant difference between the two ion channel inhibitor 283 
combinations in the time spent tracking (p = 0.601). 284 
 285 
Discussion 286 
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The aim of this study was to determine if the combination of lomerizine + oxATP + YM872, 287 
shown to effectively limit functional loss associated with secondary degeneration of the optic 288 
nerve (Savigni et al. 2013), would be as effective if oxATP was replaced with BBG, a more 289 
clinically applicable P2X7 receptor inhibitor that can cross the closed blood brain barrier. It 290 
was found that the lomerizine + BBG + YM872 combination was as effective, or marginally 291 
more effective at the tested concentrations, than the lomerizine + oxATP + YM872 292 
combination, at preserving node/paranode structure and visual function when delivered 293 
locally. However, neither therapeutic combination affected numbers of microglia and 294 
macrophages, or the number of OPCs or oligodendrocytes. The data suggest an associative 295 
relationship between preservation of myelin structure and maintenance of visual function 296 
following injury.  297 
The observed increase in nodal and paranodal lengths following partial optic nerve injury is 298 
in line with previous findings (Szymanski et al. 2013; O'Hare Doig et al. 2017) and is 299 
suggestive of myelin retraction and a breakdown of the paranodal junction 300 
(Arancibia‑Carcamo and Attwell 2014). Increased P2X7 receptor activation on the myelin 301 
sheath has also been associated with myelin degradation following injury, however the 302 
underlying cellular mechanisms remain unclear (Matute 2008). The lomerizine + BBG + 303 
YM872 combination restored nodal and paranodal structure to dimensions closer to the sham 304 
control group than the lomerizine + oxATP + YM872 combination. The lomerizine + BBG + 305 
YM872 combination was the only treatment to not be different to the sham control group for 306 
visual function. BBG is a more potent and selective antagonist of P2X7 receptors than oxATP 307 
(Donnelly-Roberts and Jarvis 2007), which may explain this marginally greater efficacy of 308 
the BBG containing combination in preserving myelin structure and visual function 309 
compared to the control groups in the current study. However, titration of doses of these 310 
agents relative to their specific inhibitory concentrations for P2X7 receptors is required to 311 
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definitively compare efficacy of the two agents within the context of this treatment 312 
combination and injury model. We have previously established that locally delivered oxATP 313 
alone does not preserve node/paranode structure nor visual function in the partial optic nerve 314 
transection model (Savigni et al. 2013). The addition of lomerizine and YM872 to the 315 
combination is required for full beneficial effects (Savigni et al. 2013), emphasising that 316 
limiting excess Ca2+ flux through voltage gated calcium channels and Ca2+ permeable AMPA 317 
receptors is also important.     318 
Following injury to the CNS, there is a high influx of Ca2+ into myelin via AMPA receptors 319 
(Fowler et al. 2003), which results in increased Ca2+ binding to the catalytic core of calpain, 320 
enhancing calpain activation (Croall and Demartino 1991; Khorchid and Ikura 2002). An 321 
increase in calpain activation can induce myelin degradation, via cleavage of myelin basic 322 
protein and myelin-associated glycoprotein (Banik et al. 1985; Shields et al. 1997; Fu et al. 323 
2007). Myelin degradation has been associated with paranodal loop eversion and sheath 324 
retraction and thus increased nodal and paranodal lengths (Ouyang et al. 2010). Therefore, 325 
observed preservation of nodal and paranodal length by both ion channel combinations may 326 
be due to inhibition of this Ca2+-dependent calpain mechanism through the antagonistic 327 
activity of YM872 on AMPA receptors.  328 
Furthermore, when the axolemma becomes exposed following myelin sheath retraction, and 329 
paranodal splitting, there is an increase in Ca2+entry into axons via sub-myelin L-type 330 
VGCCs, which are normally hidden underneath the myelin sheath (Zhang and David 2015). 331 
This contributes to neuronal Ca2+ overload, associated with oxidative stress, caspase-332 
mediated apoptosis and decreased function (Annunziato et al. 2003). Lomerizine-mediated 333 
inhibition of these sub-myelin VGCCs from beneath the sheath, together with exposure of 334 
fewer L-type VGCCs by prevention of the myelin retraction, may be a further therapeutic 335 
mechanism of the combinations of inhibitors.  336 
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Myelin structure is integral to the capacity of nerves to propagate action potentials, with the 337 
lengthening of the node associated with slower conduction velocities in a variety of 338 
pathologies (Howell et al. 2006; Reimer et al. 2011; Sun et al. 2012). Abnormal myelination 339 
at a single internode can be sufficient to block neural signal transduction for an entire axon 340 
(Baumann and Pham-Dinh 2001). Previous studies have also hypothesised that abnormalities 341 
in the node of Ranvier proteins, associated with increased nodal length, may result in 342 
decreased synchronicity of neuronal firing (Arancibia‑Carcamo and Attwell 2014). 343 
Preservation of myelin integrity by the ion channel inhibitor combinations may be facilitating 344 
action potential propagation along axons, associated with preservation of function following 345 
injury.  346 
However, in the current study myelin structure and visual function were only partly preserved 347 
by the ion channel inhibitor treatments, which suggests some aspects of myelin breakdown 348 
following injury are mediated via alternative mechanisms of damage. One potential 349 
mechanism is immune-cell mediated depletion of OPCs. The current study found that 350 
following injury, there is a significant increase in infiltrating microglia and macrophages, but 351 
not resident microglial cells, indicative of an infiltrating immune response. However, 352 
treatment did not show a significant effect at ameliorating this infiltrating immune response. 353 
Following neurotrauma, inflammatory cells produce cytokines and chemokines, as well as 354 
reactive oxygen species, resulting in oxidative damage of surrounding tissue (Anderson 355 
2002). OPCs are especially vulnerable to oxidative stress and apoptosis following injury 356 
(Thorburne and Juurlink 1996; Giacci et al. 2018), which may be why the combinations of 357 
ion channel inhibitors were unable to ameliorate the loss of OPCs in this study. OPCs are 358 
required for oligodendrogenesis and remyelination following injury (Mirron et al. 2011). 359 
OPCs also contribute to the formation of myelin nodal structures (Butt et al. 2004). It may be 360 
that significantly preserving OPCs following injury, perhaps through preventing this 361 
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infiltrating immune response, would be associated with a complete preservation of myelin 362 
structure and thus visual function. Furthermore, given previous studies have found an 363 
increased therapeutic effect of the lomerizine + oxATP + YM872 combination after three 364 
months of administration compared to three days (Savigni et al. 2013; O'Hare Doig et al. 365 
2017), it may be that a longer duration of treatment would provide further improvements to 366 
these outcomes following injury.  367 
This study showed that the combination of lomerizine + BBG + YM872, which has the 368 
potential to be delivered systemically following injury, shows promise for limiting secondary 369 
degeneration following neurotrauma, however further work remains to be done. While BBG 370 
is a highly selective P2X7 receptor antagonist, it is 30 to 50 times more potent in rats than 371 
humans (Jiang et al. 2000), which will necessitate careful titration of dosages before clinical 372 
translation will be feasible. Lomerizine is currently used in clinical practice (Hara et al. 373 
1999), YM872 is more soluble than other Ca2+  permeable AMPA receptor inhibitors 374 
(Takahashi et al. 2002) and has been trialled in stroke with an acceptable safety profile 375 
(Labiche and Grotta 2004) and BBG has no-observed-adverse-effect level of 8966mg/kg per 376 
day in a mouse model of lifetime toxicity (Borzelleca et al. 1990). Nevertheless, while no 377 
adverse effects have been observed in our rodent model, the combination of three ion channel 378 
inhibitors will need to be careful assessed for toxicity in humans before a trial of efficacy 379 
following neurotrauma can be contemplated. Furthermore, given the clinical need for 380 
systemically administered drug delivery following neurotrauma, the efficacy of this blood 381 
brain barrier permeable combination of lomerizine + BBG + YM872 needs to be tested when 382 
systemically delivered following injury.   383 
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Figure Legends 529 
Fig. 1 Effects of ion channel inhibitor combinations on densities of Iba1+ and ED1+ cells. 530 
Densities of Iba1+ (a), ED1+ (b) and Iba1+/ED1+ (c) cells in the ventral optic nerve from 531 
sham injured, vehicle treated animals, injured, vehicle treated animals, and ion channel 532 
inhibitor treated animals 3 days after partial optic nerve transection. N = 7 - 10 rats per group; 533 
graphs display min to max values, with the central line representing the median data point. 534 
Significant differences are indicated by * (p ≤ 0.05). (d) Representative images of Iba1+, 535 
ED1+ and Iba1+/ED1+ cells, indicated with arrow heads; scale bar = 10µm 536 
 537 
Fig. 2 Effects of ion channel inhibitor combinations on oligodendroglial cells. Densities of 538 
Olig2+ oligodendroglial cells (a) and PDGFαR+/Olig2+ OPCs (c) in the ventral optic nerve 539 
from sham injured, vehicle treated animals, injured, vehicle treated animals, and ion channel 540 
inhibitor treated animals, 3 days after partial optic nerve transection. N = 8 - 10 rats per 541 
group. Graphs display min to max values, with the central line representing the median data 542 
point. Significant differences are indicated by ** (p ≤ 0.01). Representative image of Olig2+ 543 
cells (b) and OPCs (d), indicated with arrow heads; scale bar = 15µm and 10µm respectively 544 
 545 
Fig. 3 Effect of ion channel inhibitor combinations on node/paranode complexes. Paranode 546 
length (a), paranodal gap length (b) and percentage of atypical node/paranode complexes (c) 547 
from thirty nodal complexes per animal in the ventral optic nerve from sham injured, vehicle 548 
treated animals, injured, vehicle treated animals, and ion channel inhibitor treated animals 3 549 
days after partial optic nerve transection. Graphs display min to max values, with the central 550 
line representing the median data point; N = 6 - 9 rats per group. Significant differences 551 
indicated by * p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 0.001. Differences compared to the sham 552 
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injured, vehicle treated group are indicated by *, differences compared to the injured, vehicle 553 
treated group are indicated by #. (d) Representative image of two Caspr+ areas flanking a β-554 
III tubulin+ area i.e. a typical nodal complex; scale bar = 2µm. (e) Representative image of 555 
one Caspr+ area flanking a β-III tubulin+ area denoting an atypical nodal complex / 556 
heminode; scale bar = 2µm 557 
 558 
Fig. 4 Effects of injury and ion channel inhibitor combinations on the number of responses in 559 
the optokinetic nystagmus test of visual function. Total number of smooth pursuits and fast 560 
resets per minute engaged in the task (a) and proportion of time paying attention to task 561 
engaged in smooth pursuits (b) by sham injured, vehicle treated animals; injured, vehicle 562 
treated animals; or injured ion channel inhibitor treated animals. Graphs display min to max 563 
values, with the central line representing the median data point; N = 5 - 10 rats per group. 564 
Significant differences are indicated by * p ≤ 0.05, ** p ≤ 0.01, and *** p ≤ 0.001. 565 
Differences compared to the sham injured, vehicle treated group are indicated by *, 566 
differences compared to the injured, vehicle treated group are indicated by # 567 
